Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab plus Paclitaxel in Metastatic Gastric Cancer
NCT03751761Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Jun 2018
- Primary completion
- Aug 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab and tremelimumab in gastric cancer (GC), sponsored by Asan Medical Center. Started Jun 2018; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03751761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03751761.